Clovis Oncology Inc. (CLVS) Lifted to Buy at Vetr Inc.
Vetr upgraded shares of Clovis Oncology Inc. (NASDAQ:CLVS) from a sell rating to a buy rating in a report issued on Monday morning. They currently have $39.27 price objective on the biopharmaceutical company’s stock.
CLVS has been the topic of several other reports. Stifel Nicolaus set a $45.00 price target on shares of Clovis Oncology and gave the company a buy rating in a research report on Wednesday, October 5th. SunTrust Banks Inc. restated a buy rating and set a $27.65 target price on shares of Clovis Oncology in a research report on Wednesday, September 14th. Janney Montgomery Scott lowered shares of Clovis Oncology from a buy rating to a neutral rating and raised their target price for the stock from $35.00 to $36.00 in a research report on Wednesday, September 21st. JPMorgan Chase & Co. restated a hold rating and set a $13.00 target price on shares of Clovis Oncology in a research report on Tuesday, August 9th. Finally, Piper Jaffray Cos. restated a neutral rating and set a $14.00 target price on shares of Clovis Oncology in a research report on Thursday, August 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $36.41.
Clovis Oncology (NASDAQ:CLVS) opened at 34.27 on Monday. The firm’s market cap is $1.32 billion. The firm has a 50 day moving average of $32.38 and a 200 day moving average of $23.00. Clovis Oncology has a 1-year low of $11.57 and a 1-year high of $40.29.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.95) by $0.25. During the same quarter last year, the business earned ($2.62) earnings per share. On average, equities research analysts expect that Clovis Oncology will post ($8.97) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Clovis Oncology Inc. (CLVS) Lifted to Buy at Vetr Inc.” was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at http://www.dailypolitical.com/2016/12/01/clovis-oncology-inc-clvs-lifted-to-buy-at-vetr-inc.html.
Institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP acquired a new position in shares of Clovis Oncology during the third quarter worth approximately $103,000. BlackRock Inc. increased its position in shares of Clovis Oncology by 12.4% in the third quarter. BlackRock Inc. now owns 2,875 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 318 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in shares of Clovis Oncology during the second quarter worth approximately $144,000. Fox Run Management L.L.C. acquired a new position in shares of Clovis Oncology during the second quarter worth approximately $154,000. Finally, DIAM Co. Ltd. acquired a new position in shares of Clovis Oncology during the third quarter worth approximately $168,000.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.